Cost-effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: An Economic Evaluation
Abstract
Familial hypercholesterolemia is an autosomal inherited genetic disorder characterized by high levels of low-density lipoprotein cholesterol circulating in the bloodstream. If left untreated, this condition can substantially increase cardiovascular risk, lead to the rapid development of premature coronary artery disease, or cause sudden cardiac death. Despite the high risks associated with familial hypercholesterolemia, a considerable number of these individuals are unable to achieve adequate reductions in low-density lipoprotein cholesterol levels with conventional lipid lowering therapy. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are emerging pharmacological treatments for managing patients with these conditions. Therefore, the goal of this thesis is to assess the cost-effectiveness of PCSK9 inhibitors for the treatment of elevated low-density lipoprotein cholesterol in individuals with familial hypercholesterolemia.
Description
Keywords
Health Care Management, Public Health
Citation
Zhang, Z. (2017). Cost-effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: An Economic Evaluation (Master's thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca. doi:10.11575/PRISM/25475